Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Early stopping designs based on progression-free survival at an early time point in the initial cohort.

Litwin S, Wong YN, Hudes G.

Stat Med. 2007 Oct 30;26(24):4400-15.

PMID:
17345568
2.

Phase II stopping rules that employ response rates and early progression.

Goffin JR, Tu D.

J Clin Oncol. 2008 Aug 1;26(22):3715-20. doi: 10.1200/JCO.2007.14.1044.

PMID:
18669457
3.

A predictive probability design for phase II cancer clinical trials.

Lee JJ, Liu DD.

Clin Trials. 2008;5(2):93-106. doi: 10.1177/1740774508089279.

PMID:
18375647
4.

Optimal and minimax three-stage designs for phase II oncology clinical trials.

Chen K, Shan M.

Contemp Clin Trials. 2008 Jan;29(1):32-41. Epub 2007 May 6.

PMID:
17544337
5.
6.
7.

Interim futility analysis with intermediate endpoints.

Goldman B, LeBlanc M, Crowley J.

Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648.

PMID:
18283075
8.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

PMID:
18477802
9.
10.

Optimizing randomized phase II trials assessing tumor progression.

Stone A, Wheeler C, Carroll K, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):146-52. Epub 2006 May 19.

PMID:
16807129
11.

A review of methods for futility stopping based on conditional power.

Lachin JM.

Stat Med. 2005 Sep 30;24(18):2747-64. Review.

PMID:
16134130
12.

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC; NET-PD Investigators.

Neurology. 2006 Mar 14;66(5):628-33. Review.

PMID:
16534099
13.

Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.

Kocherginsky M, Cohen EE, Karrison T.

J Biopharm Stat. 2009;19(3):524-9. doi: 10.1080/10543400902802441.

PMID:
19384693
14.

Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.

Hughes S, Cuffe RL, Lieftucht A, Garrett Nichols W.

Pharm Stat. 2009 Jan-Mar;8(1):25-37. doi: 10.1002/pst.323.

PMID:
18383194
15.

Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.

Kovalchik S, Mietlowski W.

Contemp Clin Trials. 2011 Jan;32(1):99-107. doi: 10.1016/j.cct.2010.09.010. Epub 2010 Oct 13.

PMID:
20920605
16.

Stochastically curtailed phase II clinical trials.

Ayanlowo AO, Redden DT.

Stat Med. 2007 Mar 30;26(7):1462-72.

PMID:
16900560
17.

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

Goffin JR, Pond GR.

BMC Med Res Methodol. 2011 Dec 12;11:164. doi: 10.1186/1471-2288-11-164.

18.

Designing phase II studies in cancer with time-to-event endpoints.

Owzar K, Jung SH.

Clin Trials. 2008;5(3):209-21. doi: 10.1177/1740774508091748.

PMID:
18559409
19.

Randomized phase II trials with a prospective control.

Jung SH.

Stat Med. 2008 Feb 20;27(4):568-83.

PMID:
17573688
20.

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2008 Apr;10(2):162-70. doi: 10.1215/15228517-2007-062. Epub 2008 Mar 4.

Supplemental Content

Support Center